$59.59
1.71% today
Nasdaq, Feb 05, 04:16 pm CET
ISIN
US00182C1036
Symbol
ANIP

ANI Pharmaceuticals, Inc. Stock price

$58.59
+3.99 7.31% 1M
-0.57 0.96% 6M
+3.31 5.99% YTD
+2.55 4.55% 1Y
+20.22 52.70% 3Y
-3.78 6.06% 5Y
+3.11 5.61% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.68 1.17%
ISIN
US00182C1036
Symbol
ANIP
Sector
Industry

Key metrics

Market capitalization $1.23b
Enterprise Value $1.73b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 22.70
EV/Sales (TTM) EV/Sales 3.11
P/S ratio (TTM) P/S ratio 2.22
P/B ratio (TTM) P/B ratio 3.04
Revenue growth (TTM) Revenue growth 23.60%
Revenue (TTM) Revenue $555.46m
EBIT (operating result TTM) EBIT $9.60m
Free Cash Flow (TTM) Free Cash Flow $76.15m
Cash position $153.32m
EPS (TTM) EPS $-0.54
P/E forward negative
P/S forward 2.06
EV/Sales forward 2.89
Short interest 14.14%
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
83%
Hold
17%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
555 555
24% 24%
100%
- Direct Costs 284 284
27% 27%
51%
272 272
20% 20%
49%
- Selling and Administrative Expenses 164 164
81% 81%
30%
- Research and Development Expense 38 38
28% 28%
7%
70 70
34% 34%
13%
- Depreciation and Amortization 60 60
1% 1%
11%
EBIT (Operating Income) EBIT 9.60 9.60
79% 79%
2%
Net Profit -8.90 -8.90
167% 167%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows:
Neutral
PRNewsWire
23 days ago
Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries   DURHAM, N.C. , Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries.
Neutral
GlobeNewsWire
23 days ago
BAUDETTE, Minn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today affirmed its prior net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS guidance for 2024 and provided its preliminary financial outlook for 2025. Nikhil Lalwani, ANI's President and Chief Executive Officer, will discuss these updates as part of a presentat...
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 642
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today